Skip to search formSkip to main contentSkip to account menu

suvorexant 15 MG Oral Tablet [Belsomra]

Known as: Belsomra 15 MG Oral Tablet, suvorexant 15 mg ORAL TABLET, FILM COATED [BELSOMRA] 
National Institutes of Health

Related topics

Related topics

11 relations
BelsomraCroscarmellose SodiumLactose MonohydrateMagnesium stearate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan
Abstract Objective: Global Phase III trials of suvorexant showed no obvious differences in the safety and efficacy profile of… 
Review
2016
Review
2016
Belsomra®: A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia
Insomnia is a disease state characterized by a persistent difficulty in falling asleep, and results in enormous health-related… 
2015
2015
Case History: Belsomra® (Suvorexant), a First-in-class Dual Orexin Receptor Antagonist for the Treatment of Insomnia
2014
2014
Insomniacs get new mechanism sleep drug Belsomra
volume 32 NumBeR 10 oCToBeR 2014 nature biotechnology Therapeutics in the University of Melbourne, in Melbourne, Australia. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)